Skip to main content

Table 1 Baseline characteristics of patients treated with HAIC for advanced hepatocellular carcinoma

From: Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A

Characteristic  
Mean age (years) 53.7 ± 9.0
Gender, male 93 (90.3%)
Etiology  
 HBV 80 (77.7%)
 HCV 4 (3.9%)
 Alcohol 8 (7.7%)
 Others 11 (10.7%)
Preoperative laboratory test  
 Total bilirubin (mg/dL) 1.1 ± 0.6
 PT (%) 92.7 ± 16.0
 Albumin (g/dL) 3.9 ± 0.5
 Platelet count (×103/μL) 184.5 ± 89.4
 AFP (ng/mL) 10587.7 ± 25449.0
 PIVKA-II (mAU/mL) 7386.3 ± 19924.9
Tumor size (mm) 70.9 ± 39.8
Tumor number  
Single 19 (18.4%)
Multiple 84 (81.6%)
Bilobar HCC 59 (57.3%)
PVTT 69 (67.0%)
Extrahepatic metastasis 20 (19.4%)
 Lung 8 (7.7%)
 Lymph node 9 (8.7%)
 Lung and lymph node 1 (1.0%)
 Bone 1 (1.0%)
 Adrenal gland 1 (1.0%)
HAIC cycle 5.7 ± 2.3
Previous locoregional treatment 35 (34.0%)
  1. HAIC hepatic arterial infusion chemotherapy, SD standard deviation, HBV hepatitis B, HCV hepatitis C, PT prothrombin time, AFP alpha-fetoprotein, PIVKA-II proteins induced by vitamin K antagonist-II, HCC hepatocellular carcinoma, PVTT portal vein tumor thrombus